Two and a half years after Sanofi unveiled to investors a revamped strategy to create an mRNA seasonal flu vaccine, Fierce Biotech has learned that the French pharma has put this pipeline on ice.

Since the announcements by federal health authorities earlier this year that federal mRNA vaccine funding will be curtailed, a fierce debate has taken place around the future of mRNA-based vaccines ...